Neuphoria Therapeutics Inc.
NEUP
$6.80
$0.182.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2,163.47% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2,163.47% | -- | |||
| Cost of Revenue | -6.97% | -8.62% | |||
| Gross Profit | 1,345.83% | 43.48% | |||
| SG&A Expenses | -46.49% | 57.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.42% | 13.80% | |||
| Operating Income | 452.40% | 4.78% | |||
| Income Before Tax | 678.82% | -106.16% | |||
| Income Tax Expenses | -800.00% | 108.77% | |||
| Earnings from Continuing Operations | 679.54% | -141.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 679.54% | -141.46% | |||
| EBIT | 452.40% | 4.78% | |||
| EBITDA | 475.63% | 5.02% | |||
| EPS Basic | 631.03% | -411,133.33% | |||
| Normalized Basic EPS | 630.40% | -383,100.00% | |||
| EPS Diluted | 630.92% | -411,133.33% | |||
| Normalized Diluted EPS | 630.40% | -383,100.00% | |||
| Average Basic Shares Outstanding | 9.14% | -99.94% | |||
| Average Diluted Shares Outstanding | 9.14% | -99.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||